Amy P. Abernethy, MD is
Associate Professor of Medicine, Duke University School of Medicine;
Director, Duke Center for Learning Health Care; Senior Fellow with the Duke
Center for Clinical Health Policy Research; faculty in the Duke Clinical
Research Institute; and, an active clinician in both outpatient and inpatient
oncology. Dr. Abernethy was also recently appointed to the National Cancer
Policy Forum with the Institute of Medicine.
A NIH and AHRQ funded
investigator with a substantial portfolio focused on comparative
effectiveness research (CER) and patient reported outcomes in cancer, Dr.
Abernethy founded and directs the Duke Cancer Care Research Program (DCCRP).
DCCRP is developing a new model of combined clinical/research inquiry in
oncology, and IT-based methods to support it, in order to facilitate
personalized CER. This model, the “rapid learning cancer clinic,” uses
electronic patient-reported outcomes as the foundation for a real-time linked
data system designed to facilitate evidence-based, individualized care as an
integral component of routine cancer care in the 21st century. Approaches
fundamentally rely on principles of data interoperability and sharing, and
Dr. Abernethy is leading Duke’s efforts to create a transferable model of a
learning healthcare system.
Dr. Averbuch is currently Vice
President, Translational Clinical Development & Pharmacodiagnostics,
Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA. In this role, Steve serves as the Executive
Sponsor of the Translational R&D teams across the Full Development and
Life Cycle Management pipeline while working to optimize knowledge sharing
and biomarker tools across all of R&D to achieve stratified medicine
development. Steve also leads the
Pharmacodiagnostics Center of Excellence with its mission to drive strategy
and execute on the integrated co-development and co-commercialization of
diagnostic tests as companions to BMS products.
Steve joined BMS in 2006. Previously he co-led the Oncology early
strategy team and he was the executive sponsor for Oncology Transition Teams
for the execution of Phase 2 Oncology programs. He has made significant Global Clinical
Research contributions to business development and he has participated in
seven successful acquisitions
Steve previously held
positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School
of Medicine. He received his M.D. and
Internal Medicine training from the University of Illinois, Chicago and his Medical
Oncology training at the National Cancer Institute in Bethesda, Maryland.
Dr. Averbuch has authored over
60 peer reviewed publications and book chapters and he is a co-author on one
patent. He is currently on the
Advisory Board for the University of Kansas Institute for Advancing Medical Innovation. He is a member of the American Society of
Clinical Oncology and the American Association for Cancer Research having
served on multiple committees for both organizations.
Mr. Balthrop has been Chief
Executive Officer and President of Luminex Corporation since May 2004. Since
he joined Luminex, the company has increased revenue over six fold at a
compound annual revenue growth of 25%. During this period R&D investment has
grown even faster at 30% while corporate gross margins have increased from
less than 45% to almost 70%. Luminex has been recognized as an innovation
leader, having introduced a number of groundbreaking, first-of-their-kind
products in infectious disease, genetic disease, personalized medicine and
complex multiplexing instrument systems.
In recent years, Luminex has
been awarded the prestigious Prix Galien Award, considered the industry
equivalent to the Nobel Prize, for Best Medical Technology based on the
company’s innovative products, as well as additional awards for design
excellence. Luminex has also consistently been honored as one of the 25
fastest growing technology companies in America by Forbes, and as one of the
100 fastest growing companies across all industries by Fortune.
Before joining Luminex, Mr.
Balthrop was President of Fisher Healthcare, a $1 billion integrated
business. Prior to Fisher, Mr. Balthrop served in a number of leadership
positions for 20 years around the globe with Abbott in diagnostics and
vascular devices. His career experience has included R&D, worldwide
commercial operations, manufacturing, international general management and
intellectual property management.
Mr. Balthrop was educated at
Northwestern University's Kellogg School of Management, Princeton University
and Spring Hill College. He holds an MBA and a BS in Biology.
Board certified internist and
clinical geneticist, Dr. Paul R. Billings serves as Chief Medical Officer of
Life Technologies Corporation (NASDAQ: LIFE), a unique position aimed at
improving patient care through expanding the use of medically relevant genomic
technologies in clinical settings. Dr. Billings has extensive expertise and
health care experience in the areas of genomics and molecular medicine. He
currently serves on the Scientific Advisory Board of the Food and Drug
Administration, the Genomic Medicine Advisory Committee at the Department of
Veterans Affairs, and the National Academy of Sciences Institute of
Medicine’s Roundtable on Genomics. Most recently, Dr. Billings was the
Director and Chief Scientific Officer of the Genomic Medicine Institute at El
Camino Hospital, the largest community hospital in the Silicon Valley. He was
also a member of the United States Department of Health and Human Services
Secretary's Advisory Committee on Genetics, Health and Society before it was
disbanded. Dr. Billings has had a distinguished career as a physician and
researcher. He has been a founder or chief executive officer of companies
involved in genetic and diagnostic medicine including GeneSage Inc., Omicia
Inc. and CELLective Dx Corporation and was senior vice president for
corporate development at Laboratory Corporation of America Holdings (NYSE;
LH). He has held academic appointments at some of the most prestigious
universities in the United States including Harvard University, U.C. San
Francisco, Stanford University and U. C. Berkeley, and has served as a
physician at a number of prestigious medical centers. He is the author of
nearly 200 publications and books on experimental and clinical medicine. His
work on genetic discrimination was instrumental in the creation and passage
of the federal Genetic Information Non-Discrimination Act of 2008. Dr.
Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology
from Harvard University. Dr. Billings is a Director of Ancestry.com (NASDAQ:
ACOM), the world leader in consumer genealogy and is a long time Board Member
of the Council for Responsible Genetics, the country’s oldest independent
biotechnology “watchdog” organization.
Jeffrey Cossman, M.D. is the
Founder and President of United States Diagnostics Standards, Inc., (USDS) an
independent certification body for laboratory and pathology diagnostics. USDS
is dedicated to improving the regulatory and commercialization pathways for
laboratory diagnostics by verifying the analytical and clinical performance
of laboratory diagnostics.
Dr. Cossman is a pathologist
and served as Chairman of the Department of Pathology at Georgetown
University and as the Oscar B. Hunter Professor of Pathology at
He founded one of the nation’s
first Molecular Diagnostics Laboratories while at the National Cancer
Institute, where he developed and implemented lymphoma molecular diagnostic
tests now in use worldwide. He has also been Vice President and Medical Director
of Gene Logic and Chief Science Officer of the Critical Path Institute. Dr.
Cossman is a co-founder of Halcyon Diagnostics, Inc., Avalon Pharmaceuticals
(now Clinical Data, Inc.), and the Association for Molecular Pathology.
Dr. Cossman has authored 150
scientific publications including the book, Molecular Genetics in Cancer
Diagnosis and has several patents in molecular diagnostics. He received his
M.D. from the University of Michigan Medical School, is board-certified in pathology
and trained in pathology at the University of Michigan, Stanford University
Donna Cryer is the President
and CEO of the American Liver Foundation, the largest and oldest national
non-profit organization serving liver disease patients and their families.
Prior to this appointment, she was the chief executive officer of CryerHealth,
an international healthcare consulting firm focused on patient engagement and
Ms. Cryer’s almost two decades
of diverse experiences have provided her with a 360 degree perspective on
health care, spanning associations, hospital consulting, PR and clinical
trial recruitment firms. Her journey as a patient advocate began with her own
liver transplant and a desire to improve the health care system for other
patients, first manifesting in a position as patient affairs specialist for
the United Network for Organ Sharing. Ms. Cryer subsequently worked with
hospital C-suite and cancer center directors at the Advisory Board Company
and Association for Community Cancer Centers. She helped rebuild the health
care practice at public relations powerhouse Hill & Knowlton’s
Washington, DC office and the multicultural practice of clinical trial
recruitment firm Matthews Media Group (now part of Ketchum). Ms. Cryer has
created successful patient education, outreach, and recruitment campaigns and
coalitions in oncology, cardiology, neurology, and renal health.
A graduate of
Harvard/Radcliffe Colleges and Georgetown University Law Center, Ms. Cryer is
a member of the Virginia State Bar.
She sits on many advisory boards and is currently serving a five-year
term as a patient representative to the U.S. Food and Drug Administration.
Dr. William (Bill) S. Dalton
is President, Chief Executive Officer and Center Director of Moffitt Cancer
Center and Research Institute, an NCI-Designated Comprehensive Cancer Center,
and serves as Board Chairman of M2Gen, a national biotechnology subsidiary of
Moffitt Cancer Center. A nationally renowned cancer researcher, physician and
health policy expert, Dr. Dalton has dedicated his career to the study and
development of the most effective approaches to cancer research and care. For
his leadership in the development of personalized cancer care and
patient-centered outcomes research, Dr. Dalton was recognized as the 2010
recipient of the Personalized Medicine Coalition’s Leadership in Personalized
Dr. Dalton currently serves as
the President-Elect of the Association of American Cancer Institutes and is
Chair of the Science Policy & Legislative Affairs Committee of the
American Association for Cancer Research. In addition, Dr. Dalton serves on the
Institute of Medicine’s, National Cancer Policy Forum and served on the
National Cancer Institute (NCI) Board of Scientific Advisors as well as
multiple scientific advisory boards at cancer centers and research
foundations across the U.S.
Mr. de Crescenzo is Senior Vice President
and General Manager for Health Sciences at Oracle Corporation. He is responsible for managing Oracle’s
solution groups, strategic planning, product development, sales, service and
support for the industry solutions sold into the healthcare and life sciences
markets worldwide. He brings over 20
years of operational and IT leadership across healthcare and life sciences to
his work with customers and partners worldwide. Oracle is the world's leading supplier of
enterprise software and related services, with over $37B in revenues and over
Prior to joining Oracle, Mr. de Crescenzo
held a number of leadership positions at IBM Corporation for a decade,
working with healthcare and life sciences clients worldwide. Prior to entering the information technology
industry, he held leadership positions in healthcare operations at medical
centers and a major health insurer.
Mr. de Crescenzo has been a keynote
speaker at numerous industry conferences worldwide and is quoted frequently
on industry issues. In 2005, he was
named one of the Top 25 Most Influential Consultants in the United States by
Consulting Magazine. Mr. de Crescenzo
has a B.A. in Political Science from Yale University and an MBA in High
Technology from Northeastern University.
Dr. Eck is Vice President and Global Head
of Oncology Medical Sciences at Astellas Pharma Global Development
(Headquartered in Northbrook, IL). He is directly responsible for the
oversight of oncology drug development plans. Much of this work is focused on
special cancer populations for which unique biology enables the development
of personalized cancer therapies. Dr. Eck previously served as Vice
President, Translational Medicine & Pharmacogenomics at Eli Lilly and
Company (2007-2011) where he was responsible for the clinical pharmacology
components of drug development including both early phase clinical studies
and late stage drug development studies. His group also developed the
biomarkers and companion diagnostics needed for effective decision-making and
for tailoring therapeutics to the right patient population. Prior to Joining
Lilly, Dr. Eck served in a variety of drug development leadership roles at
Pfizer, Inc (2002-2007).
Dr. Eck is a board certified
Hematologist/Oncologist with broad drug development experience in Oncology
and Neuroscience. He is a Fellow of the American Association for the
Advancement of Science (Pharmaceutical Sciences). He serves on the Scientific
Advisory Board of the ACGT Foundation (which supports academic cancer
research), and is a member of the Executive Committee of the Fairbanks
Institute (an institution dedicated to developing data banks to enable
personalized medicine). He also serves on the Advisory Board of the Keck
Graduate School (Claremont, CA).
Felix Frueh is a thought leader in
personalized medicine with 15 years of R&D, management and policy
experience. He is currently
Entrepreneur-in-Residence at Third Rock Ventures in Boston, where he provides
strategic input on new and existing portfolio companies with a particular
focus on personalized medicine. He is
also Executive Partner at Opus Three LLC, a consulting firm specializing in
scientific, regulatory and reimbursement strategies for the clinical
application of personalized medicine.
Prior, Felix was President of the Medco
Research Institute, leading Medco’s real-world, outcomes-oriented research
initiatives and collaborations after having formed Medco’s personalized
medicine research and development organization. Felix was the first Associate
Director for Genomics at the U.S. FDA, where he built and led the core
genomics review team in CDER, and chaired the first FDA-wide,
interdisciplinary pharmacogenomics review group (IPRG). Before joining FDA,
he was Managing Partner at Stepoutside Consulting, and held senior positions
at Transgenomic and Protogene Laboratories.
Dr. Frueh’s academic career includes a
faculty appointment at the Departments of Pharmacology and Medicine at
Georgetown University in Washington DC, and postdoctoral fellowships at
Stanford University and the University of Basel, Switzerland, where he also
received his Ph.D. in biochemistry.
Timothy Garnett, FRCOG, MFFP, FFPM, is
Chief Medical Officer, Senior Vice President and Co-Leader of the Development
Center of Excellence managing Medical Affairs, Global Health Outcomes,
Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly
and Company. During his 14 years at
Lilly, Dr. Garnett has served as Vice President for Global Patient Safety;
Global Brand Development Leader and Group Medical Director responsible for
the development of Duloxetine for incontinence, pain and depression; Medical
Director-Duloxetine SUI Team; and European Clinical Research Physician for
Prior to joining Lilly, Dr. Garnett had
acquired 7 years of experience, holding a variety of positions in the
pharmaceutical industry in Europe with Organon Laboratories.
He qualified in Medicine at St. George's
Hospital in London. Dr. Garnett is a
Fellow of the Royal College of Obstetricians and Gynecologists in the United
Kingdom. He is also an active board
member of the following: Centre for
Innovation in Regulatory Science; Indiana Health Industry Forum; and
Eiteljorg Museum of American Indians and Western Art.
Julie K. Goonewardene is a recognized
leader in technology commercialization, business formation, and
public/private partnerships. Based on her successes in these areas, Ms.
Goonewardene was recently elected to the Board of Trustees for the American
Medical Association (AMA).
In addition to serving in her current
role as Associate Vice Chancellor for Innovation and Entrepreneurship at the
University of Kansas (KU), she is president of the KU Center for Technology
Commercialization and a professor of practice in the KU School of Business.
Ms. Goonewardene is responsible for all university-wide commercialization
efforts with the intellectual property, company formation, corporate outreach
and foundation research relationship groups reporting to her.
Prior to KU, she held various roles at
Purdue University. One of her primary focus areas was company formation and
capital acquisition for start-up companies. While at Purdue she designed and
managed Purdue’s first venture fund. Ms. Goonewardene is an experienced
entrepreneur herself, having co-founded and served as president and CEO of
Cantilever Technologies, a venture-backed software company that was
successfully acquired in 2004.
Ms. Goonewardene earned a B.S. degree
with Honors in Management and a master’s degree in Health Communication from
Purdue University and is currently a member of The Economic Club of Chicago
and The Chicago Finance Exchange.
Michael Kolodziej M.D. is the National
Medical Director, Oncology Solutions, Office of the Chief Medical Officer,
Aetna. Dr. Kolodziej attended college and medical school at Washington
University in St. Louis. He completed internal medicine and hematology-oncology
training at the University of Pennsylvania in Philadelphia.
After completing training, Dr. Kolodziej
joined the faculty at the University Of Oklahoma School Of Medicine where he
was an associate professor.
He joined New York Oncology in the winter
of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology
Pharmacy and Therapeutics committee, on the executive committee from
2002-2011, and chairman from 2004-2011. He served as Medical Director for
Oncology Services for US Oncology from 2007-2011.In this role, he helped
direct the implementation of the USON clinical pathways initiative, the
integration of the USON EMR into this program, and the development of the
USON disease management and advanced care planning programs, now known
as Innovent Oncology.
He has published several manuscripts and given several presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost of care in oncology. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (19) and Katherine (16).
Lawrence J. Lesko, Ph.D., F.C.P. has been
leading UF’s new Center for Pharmacometrics and Systems Pharmacology in the
interdisciplinary Institute of Therapeutic Innovation at the UF Research and
Academic Center in Lake Nona (Orlando) since July 2011.
Before joining UF, Dr. Lesko worked
nearly 20 years in the Food and Drug Administration’s Center for Drug
Evaluation and Research as the Director of the Office of Clinical
Pharmacology. He was also Chair of the
Clinical Pharmacology Coordinating Subcommittee of the FDA’s Medical Policy
Coordinating Committee and authored or co-authored numerous Guidance for
Industry, and started the FDA’s Voluntary Genomics Data Submission Program
and Mechanistic Drug Safety Program.
Dr. Lesko is the recepient of numerous
awards related to his expertise in personalized medicine, and has published
more than 200 peer-reviewed scientific publications.
Brian Munroe is the founder and the
immediate Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of the
PMC Public Policy Committee and on the Executive Committee of the PMC Board
Brian is a twenty year veteran of health
care public policy, advocacy, and communications. His areas of expertise are in FDA
legislation and regulations, Medicare and Medicaid reimbursement, federal and
state tax policy, and the development of government policies to advance
Brian has created successful, stand alone Government Affairs
Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo
Pharmaceuticals. He is currently the
Vice-President in charge of Washington office, the Public Policy group, State
Government Relations and, the Political Action Committee at Endo. He also serves on Endo’s Executive
Brian’s breadth in health care policy
stretches across pharma /biotech, home health care, diagnostics, medical
devices, clinical laboratories, and health care payors. His geographical responsibilities have
included the fifty states, the Federal government and Congress, and for a
short time the European Union and member countries.
Brian began his career in Washington,
D.C. working for United States Senator Alan Cranston (D-CA).
Brian currently lives in the
Washington, D.C. area with his wife
Vicky and their four children.
D. Stafford O'Kelly, retired, was
formerly President of Abbott Molecular.
He served in this role from 2007-2012.
Mr. O'Kelly joined Abbott in 1984 and
served in various management positions. These included Vice President, Latin
America/Canada Operations; Division Vice President Finance, Abbott
International, Division; Vice President
and Controller, Ross Products Division (now Abbott Nutrition); and Vice
President Finance, TAP
Mr. O'Kelly serves on the boards of Youth
Conservation Corps, Inc., and the Clara Abbott Foundation.
He has a bachelor's degree in engineering
and MBA from Trinity College in Dublin, Ireland.
Aidan Power joined Pfizer in the United
Kingdom in 1993 working on the antidepressant, Sertraline, and the
antipsychotic, Ziprasidone where he planned, designed and managed
multi-national, large-scale Phase III clinical trials. He established a Clinical Pharmacogenetics
group in Pfizer in the UK in 1998 and built the framework for the use of
genetics in clinical development also establishing the practice of biobanking
samples from clinical trials. In 2002, he relocated to Pfizer Global Research
and Development Headquarters in New London, Connecticut, and established the
Clinical Pharmacogenomics Group. Most
recently, as Vice President and Head of PharmaTherapeutics Precision Medicine
(formerly Molecular Medicine) at Pfizer, he leads a team that integrates
molecular studies across disease areas and develops diagnostics for critical
programs in the Pfizer product pipeline.
He is active in a number of groups
established to progress pharmacogenomics and personalized medicine and serves
on the board of the Serious Adverse Event Consortium (iSAEC) and the
Institute of Medicine’s Roundtable on Translating Genomics Based Research for
Dr. Power has a degree in Medicine from
University College Cork, Ireland, and trained as a psychiatrist in
England. He also obtained a MSc in the
History of Science and Medicine at University College London and the Wellcome
Institute for the History of Medicine.
Lori Reilly is Vice President for Policy
& Research at the Pharmaceutical Research and Manufacturers of America
(PhRMA). Ms. Reilly oversees PhRMA’s
development of legislative and policy analysis and research studies on health
care issues including pharmaceutical economics and utilization, health care
quality, direct-to-consumer (DTC) advertising/marketing and promotion, import
safety, comparative effectiveness and intellectual property.
In addition to her public policy work,
Ms. Reilly is a frequent presenter on industry-related issues and is an
industry spokesperson, appearing regularly on CNN, Fox News, ABC News, MSNBC
and a host of other media outlets. Ms.
Reilly testified before the House Energy and Commerce Subcommittee on Health
to discuss the importance of reauthorization of the pediatric exclusivity
program and the Food and Drug Administration Globalization Act.
Prior to joining PhRMA, she was counsel
at the U.S. House of Representatives Committee on Commerce. And before
joining the House Commerce Committee, Ms. Reilly was Chief of Staff to Rep.
Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln (1993), where she graduated with Honors, and a J.D. from the University of Nebraska College of Law (1996). She is a Member of the Virginia Bar.
Wayne is a Distinguished Fellow at the
Center for Biomedical Innovation at MIT working on health care strategy and
policy issues related to science and medicine, a member of the Ethics and
Systems Medicine Program at Georgetown University and Chairman of the board
of directors of the Personalized Medicine Coalition. He is also VP Strategic Consulting at Fuld
& Company focusing on strategic simulations in health care, Chief
Scientific Advisor at Expertech focusing on strategic futuring for Air Force
Medical Systems, and Chief Applications Officer for SciTech Strategies
focusing on scientific competency and capacity development for academia and
industry. He is a former Director of
External Relations for Personalized Healthcare and Evidence-based Medicine
(EBM) as part of External Medical Relations at AstraZeneca where he had
responsibility for long-range external relations strategy and policy
development. Prior to that role, he
was involved in long-term strategy development for the AstraZeneca Discovery,
Development, and US Commercial divisions, and created and ran strategic
intelligence units at both AstraZeneca and SmithKIine Beecham
Pharmaceuticals. He is a former
President of SCIP (Society of Competitive Intelligence Professionals) and has
received the SCIP Fellows Award and Lifetime Achievement Award in
Intelligence from Frost and Sullivan.
Wayne is active on strategy and advisory boards of several
organizations including the IOM, IBM Life Sciences, and Hewlett-Packard Life
Sciences. He has presented at numerous
forums on aspects of personalized health care, evidence-based medicine, new
development paradigms, and strategy development. He holds a B.S. in Biology from MIT, a
Ph.D. in Cell and Molecular Biology from Boston University, and received
post-doctoral training in Cancer and Radiation Biology at the University of
Rochester. Wayne lives in Malvern,
Pa., is married with two college-age children, and enjoys teaching martial
arts (Tang Soo Do), restoring antique/classic Fords, and aviation history.
Jared N. Schwartz, M.D., Ph.D., F.C.A.P.,
brings 30 years of pathology expertise to his role as Chief Medical Officer
at Leica Biosystems. Formerly with Aperio, and previously serving as
President of the College of American Pathologists, and Director of Pathology
and Laboratory Medicine at Presbyterian Healthcare in Charlotte, North
Carolina. Board certified in anatomic and clinical pathology with
subspecialty boards in medical microbiology and cytopathology, he is a
graduate of Duke University Medical School, where he completed his residency
and fellowship training, and served as chief resident. He was appointed to
the Clinical Laboratory Improvement Advisory Committee by HHS, and was a
co-chair and author of the ASCO/CAP Guidelines on HER2, which was published
in the January 2007 editions of the Journal of Clinical Oncology and Archives
of Pathology and Laboratory Medicine and was one of authors of ASCO/CAP
Guidelines for ER/PR published in Journal of Clinical Oncology and Archives
of Pathology and Laboratory Medicine in 2010. He also serves as a Consulting
Professor of Pathology Stanford University.
Michael Vasconcelles, M.D., joined Millennium: The Takeda Oncology Company in 2012 as Senior Vice President, Head of Clinical Development. As part of Millennium's Medical Division Management and Administration, Dr. Vasconcelles has assumed responsibility for the clinical development strategy and execution of the oncology portfolio.
Prior to 2012, Dr. Vasconcelles served as
Global Therapeutic Area Head, Transplant and Oncology, at Genzyme. He was
responsible for the clinical development and product support of Genzyme's
hematologic transplant and oncology portfolio. As a member of the Transplant
and Oncology Management team, and Chair of the Transplant and Oncology
R&D Council, Dr. Vasconcelles also provided strategic support and
oversight to oncology research, business development and commercial strategy
for the business. In 2011, following the acquisition of Genzyme by Sanofi, he
led the realignment of Genzyme Oncology R&D with Sanofi Global Oncology
and was named the Head, Personalized Medicine and Companion Diagnostics.
Before he joined Genzyme, Dr.
Vasconcelles was a full time associate physician at Brigham and Women's
Hospital and Dana-Farber Cancer Institute. He remains an associate physician
at both institutions. He has been on the faculty of the Harvard Medical School
since 1996, where he is currently a clinical instructor of medicine.
Dr. Vasconcelles recieved both his B.A.
and his M.D. from Northwestern University.